Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Accuray has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The firm had revenue of $107.24 million for the quarter, compared to analyst estimates of $107.11 million. Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. During the same period in the prior year, the firm posted ($0.02) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Stock Performance

Shares of ARAY stock opened at $2.22 on Wednesday. The stock has a fifty day moving average price of $2.53 and a 200 day moving average price of $2.66. The stock has a market cap of $220.16 million, a PE ratio of -14.80 and a beta of 1.44. Accuray has a 1 year low of $2.10 and a 1 year high of $4.30. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.84 and a current ratio of 1.58.

Analyst Ratings Changes

Several equities analysts have weighed in on ARAY shares. TheStreet downgraded Accuray from a “c-” rating to a “d+” rating in a research report on Wednesday, February 14th. Roth Capital reissued a “buy” rating on shares of Accuray in a research report on Tuesday, February 13th. Finally, Roth Mkm started coverage on Accuray in a research report on Tuesday, February 13th. They set a “buy” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Accuray presently has an average rating of “Moderate Buy” and an average target price of $8.25.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.